Drugs / CD19/CD22-Dual-STAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04508842 | Oct 2020 → May 2022 | acute lymphoblastic leukemia | Hebei Yanda Ludaopei Hospital | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22-Dual-STAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04508842 ↗ |
| Route | Intravenous | “Dual-STAR-T cells will be intravenously infused” NCT04508842 ↗ |